Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 47%
Buy 53%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific demonstrated strong financial performance, highlighted by a gross margin of 70.7%, which exceeded consensus estimates and was buoyed by an improved product mix despite the impact of tariffs. The company's urology, neuromodulation, interventional cardiology, and vascular therapies segments showcased consistent growth, with respective sales increases of 3.2%, 9.9%, and 8.3% in the latest quarter, indicating robust demand for its innovative medical devices. Additionally, potential upside drivers such as accelerated growth in electrophysiology, contributions from recent acquisitions, and further margin expansion suggest a favorable outlook for future revenue streams.

Bears say

Boston Scientific's stock outlook is negatively impacted by a decline in operating margin, which decreased by 10 basis points year-over-year due to rising research and development expenses that overshadowed slight gross margin growth. Organic growth slowed to 12.7% in the fourth quarter of 2025, down from 15.3% in the previous quarter, primarily due to heightened competition and reduced adoption rates for the FARAPULSE device within the atrial fibrillation market. Additionally, the company faces a bear case scenario where sustained revenue growth is projected to remain below 10% amid potential share losses in critical markets, further contributing to an overall contraction in operating margins.

Boston Scientific (BSX) has been analyzed by 19 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 53% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 19 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.